GILD
NASDAQGilead Sciences Inc.
Price$125.05-0.58 (-0.46%)
01:30 PM07:45 PM
News · 26 weeks116-48%
2025-12-282026-06-21
Mix6590d
- Other26(40%)
- Insider22(34%)
- SEC Filings10(15%)
- Earnings3(5%)
- M&A3(5%)
- Offering1(2%)
Latest news
25 items- PREuropean Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors–Trodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer – – Authorization Based on ASCENT-03 Study in Which Trodelvy Demonstrated Highly Statistically Significant and Clinically Meaningful Progression-Free Survival (PFS) Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- PRU.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. "This filing reflects Gilead's continued commitment to advancing new HIV prevention options," said Dietmar Berger, Chief Medical Officer, Gilead Sciences. "Nea
- PRGilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak ReliefGilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (BVD). This donation, along with the additional supply being readied, continues the company's long-standing work to address emerging infectious diseases."At Gilead, we recognize the urgency and human toll of global health emergencies – and the responsibility to act quickly," said Anu Osinusi, MD, Vice President, Clinical Development, Virology at Gilead Sciences. "Building on decades of experience responding to serious infectious diseases, our teams are working along
- INSIDERChief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDEREVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- PRNational AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership- Three-year, ~$3M commitment to expand leadership development, strengthen HIV education and engagement, and preserve the HIV movement's history for future generations - The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight against HIV/AIDS has always depended on more than medicine. It has required scientific innovation, public education, activism, compassion, communities caring for one another through crisis and change, and a shared commitment to
- PRMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 StudyMerck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's Trodelvy® (sacituzumab govitecan-hziy) in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, compared to KEYTRUDA monotherapy in certain patients with previously untreated metastatic non-small cell lung cancer, whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥50%). The decision is based on the recommendation from the external Data Monitoring Committee (eDMC) following their review of the data from the pre-specified final analysis of progression-free s
- PRGilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South AfricaGilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access to lenacapavir for communities most affected by HIV. "South Africa is at the heart of global efforts to end HIV. With the country's launch of lenacapavir, there is now an opportunity to rapidly accelerate progress," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences. "Through partnerships with country leadership, the Global Fund, and the U.S. State Department via PEPFAR, Gilead is working to bring lenacapavir to the communities most in need, ahead of
- PRGILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINECompanies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif. and Mechelen, Belgium; June 4, 2026, 22.15 CET – Gilead Sciences, Inc. (NASDAQ:GILD) and Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead's growing inflammation portfolio and will be the foundation of Lakefront's clinical development pipeline. Gamgertamig is designed to
- PRGilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline– Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases – Gilead Sciences, Inc. (NASDAQ:GILD) and Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604796427/en/ The acquisition adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead's growing inflammation portfolio and will be the foundation of Lakefro
- INSIDERChairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- PRGilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA – – 52-Week Results Demonstrate High and Sustained ALP Normalization and Generally Well-Tolerated Safety Profile – – Findings Add to Growing Evidence Supporting ALP Normalization as an Achievable Treatment Goal in PBC – Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 we
- PRPhase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal Associated with Increased Risk of Disease Progression – – Further Analyses of the Phase 3 ASSURE Study Demonstrate Sustained ALP Normalization and Show Exploratory Outcomes of Stable or Improved Liver Stiffness, Providing Supportive, Long-term Evidence – Gilead Sciences, Inc. (NASDAQ:GILD) today shared new results from a post hoc analysis showing that Livdelzi® (seladelpar) was associated with high and sustained rates of normalization of a key liver marker (ALP) in people living with primary biliary cholangitis (PBC). In an ongoing Phase 3 study, participants with elevated ALP levels (betwe
- FDAFDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug HEPCLUDEX (ORIG-1) with active ingredient BULEVIRTIDE-GMOD) has changed to 'Approval' on 05/22/2026. Application Category: BLA, Application Number: 761468, Application Classification:
- PRFDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)– Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death – – Approval introduces the first FDA-approved therapy for this disease with limited treatment options and high unmet need – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with chronic hepatitis delta virus (HDV) infection, making it the first and only approved treatment for HDV in the United States. The FDA granted accelerated approval to Hepcludex based on reductions in HDV RNA
- PRGilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients– – Positive Opinion Marks a Significant Step Towards Introducing a Crucial First-line Treatment Option for People Living with Metastatic Triple-Negative Breast Cancer in the EU – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult
- PRNew ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology– ASCO Presentations on Trodelvy® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial Launches – – EHA Updates Include Durability of KITE-753, Kite's Enhanced DuoCore™ CAR T-cell Therapy – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, including six oral presentations, at the 2026 ASCO Annual Meeting (May 29 – June 2) and the 2026 EHA Congress (June 11 – 14). These presentations underscore the increasing diversity of Gilead's oncology portfolio and pipeline reflecting a growing body of evidence across both s
- FDAFDA Approval for BIKTARVY issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)
- FDAFDA Approval for BIKTARVY issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Labeling
- PRGilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio– Acquisition Builds on Gilead's Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs). The acquisition brings Gilead next-generation ADC assets and a platform designed to maximize patient benefit through more selective delivery of diverse payloads to tumors. Tubulis' technologies enable the development of unique ADCs with superior biophysical properties, capable of achieving robus
GILD FAQ
8 questionsWhat does Gilead Sciences Inc. do?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus...Where does GILD stock trade?
Gilead Sciences Inc. (GILD) is listed on NASDAQ.What sector and industry is GILD in?
Gilead Sciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Gilead Sciences Inc. go public?
Gilead Sciences Inc. (GILD) completed its IPO in 1992.Does GILD pay a dividend?
GILD's most recent ex-dividend date was 2026-06-15 with a cash dividend of $0.82 per share. No future ex-date is on file yet.What are analysts saying about GILD?
Gilead Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Maxim Group: Buy on 2026-05-20.What companies are similar to GILD?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), BMY (Bristol-Myers Squibb Company). Compare GILD side-by-side with any of them on Quantisnow.How can I track GILD on Quantisnow?
Quantisnow aggregates Gilead Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GILD to receive live email and push alerts on every new disclosure.